指南与共识泌尿生殖腹部MR

多参数磁共振成像与膀胱影像报告和数据系统(VI-RADS)用于膀胱癌诊断和分期:来自美国放射学会VI-RADS指导委员会的临床医生指南

Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
指南 / 共识 · Eur Urol · 2025-10-31

本文为美国放射学会VI-RADS指导委员会撰写的叙述性综述,旨在为泌尿外科医生提供膀胱多参数磁共振成像(mpMRI)及其在多种临床场景中应用的实用、最新概述。综述指出,mpMRI联合VI-RADS可提高术前分期准确性,有助于在部分非肌层浸润性膀胱癌病例中避免重复经尿道膀胱肿瘤电切术,并支持肌层浸润性膀胱癌基于MRI路径的决策;nacVI-RADS可评估系统治疗后的治疗反应,并可能指导保留膀胱策略。障碍包括可及性差异、指南不一致、判读可重复性及有限的成本效果数据。

要点

  • mpMRI联合VI-RADS可提高膀胱癌术前分期准确性,并支持MRI路径下的治疗决策。
  • 在部分非肌层浸润性膀胱癌病例中,VI-RADS有助于避免重复经尿道膀胱肿瘤电切术。
  • nacVI-RADS可评估系统治疗后的治疗反应,并可能指导保留膀胱策略。

核心结论

  • mpMRI、VI-RADS和nacVI-RADS是加强风险分层和个体化膀胱癌管理的重要工具,整合到多学科工作流程中有望改善结局并减少过度治疗。

研究设计与样本

  • 美国放射学会VI-RADS指导委员会撰写的叙述性综述,检索并纳入关于MRI在膀胱癌诊断和治疗路径中作用的原始研究、Meta分析、国际指南和专家共识文件。

诊断标准与关键数值

  • VI-RADS用于膀胱癌局部分期,nacVI-RADS为其新辅助化疗版本,用于系统治疗后的治疗反应评估。

临床应用与阅片要点

  • mpMRI联合VI-RADS可提高术前分期准确性,并支持肌层浸润性膀胱癌基于MRI路径的决策。
  • 在部分非肌层浸润性膀胱癌病例中,VI-RADS有助于避免重复经尿道膀胱肿瘤电切术。
  • nacVI-RADS可评估系统治疗后的治疗反应,并可能指导保留膀胱策略。
  • 将mpMRI、VI-RADS和nacVI-RADS整合到多学科工作流程中,有望改善结局并减少过度治疗。

局限性

  • 障碍包括可及性差异、指南不一致、判读可重复性及有限的成本效果数据。
  • 正在进行的多中心验证工作和标准化报告有助于缓解这些问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND OBJECTIVE: Staging of bladder cancer (BC) remains a cornerstone of treatment planning, especially in distinguishing non-muscle-invasive BC (NMIBC) from muscle-invasive BC (MIBC). Multiparametric magnetic resonance imaging (mpMRI), together with the Vesical Imaging-Reporting and Data System (VI-RADS) and its neoadjuvant chemotherapy version (nacVI-RADS), has emerged as a noninvasive, standardised tool for local staging and response assessment. Our aim was to provide urologists with a practical, up-to-date overview of bladder mpMRI and its application in diverse clinical settings.

METHODS: We conducted a narrative review of the literature, including original studies, meta-analyses, international guidelines, and expert consensus documents, on the role of magnetic resonance imaging (MRI) in the BC diagnostic and therapeutic pathway. KEY FINDINGS AND LIMITATIONS: mpMRI with VI-RADS improves the accuracy of preoperative staging, helps in avoiding repeat transurethral resection of bladder tumour in selected NMIBC cases, and supports decision-making in MIBC in MRI-based pathways. nacVI-RADS allows assessment of treatment responses after systemic therapies, and can potentially guide bladder-sparing approaches. Barriers include variability in access, guideline inconsistency, the reproducibility of interpretation, and limited cost-effectiveness data. However, ongoing multicentre validation efforts and standardised reporting are helping to mitigate these issues.

CONCLUSIONS AND CLINICAL IMPLICATIONS: mpMRI, VI-RADS, and nacVI-RADS represent essential tools for enhancing risk stratification and personalising BC management in clinical urology practice. Their integration into multidisciplinary workflows has the potential to improve outcomes and reduce overtreatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Panebianco V, Briganti A, Efstathiou JA, et al. Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee. Eur Urol. 2025. PMID: 41176432. doi:10.1016/j.eururo.2025.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。